Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kimberly Y. Won is active.

Publication


Featured researches published by Kimberly Y. Won.


American Journal of Tropical Medicine and Hygiene | 2008

National Seroprevalence and Risk Factors for Zoonotic Toxocara spp. Infection

Kimberly Y. Won; Deanna Kruszon-Moran; Peter M. Schantz; Jeffrey L. Jones

To estimate the prevalence of Toxocara spp. infection in a representative sample of the United States population >or= 6 years of age, sera from participants in the Third National Health and Nutrition Examination Survey (1988-1994) were tested for antibodies to Toxocara. Among the 30,930 persons selected for the survey, 82% (N = 25,733) were interviewed, and 91% (N = 23,527) of those interviewed underwent physical examination of which 87% (N = 20,395) were tested. The age adjusted Toxocara seroprevalence was 13.9% (95% confidence intervals [CI] 12.5, 15.3), and was higher in non-Hispanic blacks (21.2%) than non-Hispanic whites (12%) or Mexican Americans (10.7%; P < 0.001). Increased Toxocara seropositivity was associated with head of household level of education (low versus high) (odds ratio [OR]: 2.2; CI: 1.8, 2.8), poverty (OR: 1.5; CI: 1.3, 1.8), elevated blood lead concentrations (OR: 1.4; CI: 1.1, 1.9), and dog ownership (OR: 1.2; CI: 1.1, 1.4). Toxocara infection is widespread and associated with specific risk groups.


Clinical Infectious Diseases | 2001

Outbreak of cyclosporiasis associated with basil in Missouri in 1999.

Adriana S. Lopez; Douglas R. Dodson; Michael J. Arrowood; Palmer A. Orlandi; Alexandre J. da Silva; Jeffrey W. Bier; Sandra D. Hanauer; Rachelle L. Kuster; Sandy Oltman; Martha S. Baldwin; Kimberly Y. Won; Eva M. Nace; Mark L. Eberhard; Barbara L. Herwaldt

During the summer of 1999, an outbreak of cyclosporiasis occurred among attendees of 2 events held on 24 July in different counties in Missouri. We conducted retrospective cohort studies of the 2 clusters of cases, which comprised 62 case patients. The chicken pasta salad served at one event (relative risk [RR], 4.25; 95% confidence interval [CI], 1.80-10.01) and the tomato basil salad served at the other event (RR, 2.95; 95% CI, 1.72-5.07) were most strongly associated with illness. The most likely vehicle of infection was fresh basil, which was included in both salads and could have been grown either in Mexico or the United States. Leftover chicken pasta salad was found to be positive for Cyclospora DNA by means of polymerase chain reaction analysis, and 1 sporulated Cyclospora oocyst was found by use of microscopy. This is the second documented outbreak of cyclosporiasis in the United States linked to fresh basil and the first US outbreak for which Cyclospora has been detected in an epidemiologically implicated food item.


Clinical and Vaccine Immunology | 2010

Improved Diagnosis of Strongyloides stercoralis Using Recombinant Antigen-Based Serologies in a Community-Wide Study in Northern Argentina

Alejandro J. Krolewiecki; Roshan Ramanathan; Valeria Fink; Isabel McAuliffe; Silvana P. Cajal; Kimberly Y. Won; Marisa Juarez; Adriana Di Paolo; Laura Tapia; Norma Acosta; Rogan Lee; Patrick J. Lammie; David Abraham; Thomas B. Nutman

ABSTRACT The serodiagnosis of Strongyloides stercoralis infection by enzyme-linked immunosorbent assays based on crude antigen (CrAg-ELISA), while useful, has been limited by the reliance on crude parasite extracts. Newer techniques such as the luciferase immunoprecipitation system assay (LIPS), based on a 31-kDa recombinant antigen (termed NIE) from S. stercoralis and/or the recombinant antigen S. stercoralis immunoreactive antigen (SsIR), or the NIE-ELISA have shown promise in controlled settings. We compared each of these serologic assays in individuals from both regions of the world in which S. stercoralis is endemic and those in which it is not. A comprehensive stool evaluation (sedimentation concentration, Baermann concentration with charcoal cultures, agar plate, and Harada-Mori) and four different serologic techniques using CrAg-ELISA or recombinant NIE-ELISA as well as LIPS using NIE alone or in combination with a second recombinant antigen (NIE/SsIR-LIPS) were compared among individuals with parasitologically proven infection (n = 251) and healthy controls from regions of the world in which the infection is nonendemic (n = 11). Accuracy was calculated for each assay. The prevalence of S. stercoralis infection was 29.4% among Argentinean stool samples (n = 228). Sedimentation concentration and Baermann were the most sensitive stool-based methods. NIE-LIPS showed the highest sensitivity (97.8%) and specificity (100%) of the serologic assays. The calculated negative predictive value was highest for both the NIE-LIPS and CrAg-ELISA (>97%) irrespective of disease prevalence. No cross-reactivity with soil-transmitted helminths was noted. NIE-LIPS compares favorably against the current CrAg-ELISA and stool evaluation, providing additional accuracy and ease of performance in the serodiagnosis of S. stercoralis infections irrespective of disease prevalence.


PLOS Neglected Tropical Diseases | 2012

A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate bancroftian filariasis

Katherine Gass; Madsen Beau de Rochars; Daniel A. Boakye; Mark Bradley; Peter U. Fischer; John O. Gyapong; Makoto Itoh; Nese Ituaso-Conway; Hayley Joseph; Dominique Kyelem; Sandra J. Laney; Anne-Marie Legrand; Tilaka S. Liyanage; Wayne Melrose; Khalfan A. Mohammed; Nils Pilotte; Eric A. Ottesen; Catherine Plichart; K. D. Ramaiah; Ramakrishna U. Rao; Jeffrey Talbot; Gary J. Weil; Steven Williams; Kimberly Y. Won; Patrick J. Lammie

Successful mass drug administration (MDA) campaigns have brought several countries near the point of Lymphatic Filariasis (LF) elimination. A diagnostic tool is needed to determine when the prevalence levels have decreased to a point that MDA campaigns can be discontinued without the threat of recrudescence. A six-country study was conducted assessing the performance of seven diagnostic tests, including tests for microfilariae (blood smear, PCR), parasite antigen (ICT, Og4C3) and antifilarial antibody (Bm14, PanLF, Urine SXP). One community survey and one school survey were performed in each country. A total of 8,513 people from the six countries participated in the study, 6,443 through community surveys and 2,070 through school surveys. Specimens from these participants were used to conduct 49,585 diagnostic tests. Each test was seen to have both positive and negative attributes, but overall, the ICT test was found to be 76% sensitive at detecting microfilaremia and 93% specific at identifying individuals negative for both microfilariae and antifilarial antibody; the Og4C3 test was 87% sensitive and 95% specific. We conclude, however, that the ICT should be the primary tool recommended for decision-making about stopping MDAs. As a point-of-care diagnostic, the ICT is relatively inexpensive, requires no laboratory equipment, has satisfactory sensitivity and specificity and can be processed in 10 minutes—qualities consistent with programmatic use. Og4C3 provides a satisfactory laboratory-based diagnostic alternative.


Journal of Parasitology | 2000

ATTEMPTS TO ESTABLISH EXPERIMENTAL CYCLOSPORA CAYETANENSIS INFECTION IN LABORATORY ANIMALS

Mark L. Eberhard; Ynes R. Ortega; Darcy E. Hanes; Eva K. Nace; Rose Quy Do; Martin G. Robl; Kimberly Y. Won; Cesar M. Gavidia; Neil L. Sass; Keith Mansfield; Alfonso Gozalo; Jeffrey Griffiths; Robert H. Gilman; Charles R. Sterling; Michael J. Arrowood

Attempts were made to develop an animal model for Cyclospora cayetanensis to identify a practical laboratory host for studying human cyclosporiasis. Oocysts collected from stool of infected humans in the United States, Haiti, Guatemala, Peru, and Nepal were held in potassium dichromate solution to allow development of sporozoites. The following animal types were inoculated: 9 strains of mice, including adult and neonatal immunocompetent and immune-deficient inbred and outbred strains, rats, sandrats, chickens, ducks, rabbits, jirds, hamsters, ferrets, pigs, dogs, owl monkeys, rhesus monkeys, and cynomolgus monkeys. Most animals were inoculated by gavage, although some of the primates were fed oocysts on food items. The animals were examined for signs of infection, particularly diarrhea, and stool samples were examined for 4–6 wk after inoculation. None of the animals developed patent infections or signs of infection. We conclude that none of the animals tested is susceptible to infection with C. cayetanensis.


American Journal of Tropical Medicine and Hygiene | 2013

Laboratory and Field Evaluation of a New Rapid Test for Detecting Wuchereria bancrofti Antigen in Human Blood

Gary J. Weil; Kurt C. Curtis; Lawrence S. Fakoli; Kerstin Fischer; Lincoln Gankpala; Patrick J. Lammie; Andrew C. Majewski; Sonia Pelletreau; Kimberly Y. Won; Fatorma K. Bolay; Peter U. Fischer

Global Program to Eliminate Lymphatic Filariasis (GPELF) guidelines call for using filarial antigen testing to identify endemic areas that require mass drug administration (MDA) and for post-MDA surveillance. We compared a new filarial antigen test (the Alere Filariasis Test Strip) with the reference BinaxNOW Filariasis card test that has been used by the GPELF for more than 10 years. Laboratory testing of 227 archived serum or plasma samples showed that the two tests had similar high rates of sensitivity and specificity and > 99% agreement. However, the test strip detected 26.5% more people with filarial antigenemia (124/503 versus 98/503) and had better test result stability than the card test in a field study conducted in a filariasis-endemic area in Liberia. Based on its increased sensitivity and other practical advantages, we believe that the test strip represents a major step forward that will be welcomed by the GPELF and the filariasis research community.


Acta Tropica | 2011

A multicenter evaluation of a new antibody test kit for lymphatic filariasis employing recombinant Brugia malayi antigen Bm-14

Gary J. Weil; Kurt C. Curtis; Peter U. Fischer; Kimberly Y. Won; Patrick J. Lammie; Hayley Joseph; Wayne Melrose; Norbert W. Brattig

Antibody tests are useful for mapping the distribution of lymphatic filariasis (LF) in countries and regions and for monitoring progress in elimination programs based on mass drug administration (MDA). Prior antibody tests have suffered from poor sensitivity and/or specificity or from a lack of standardization. We conducted a multicenter evaluation of a new commercial ELISA that detects IgG4 antibodies to the recombinant filarial antigen Bm14. Four laboratories tested a shared panel of coded serum or plasma samples that included 55 samples from people with microfilaremic Wuchereria bancrofti or Brugia infections and 26 control samples. Qualitative results were identical in all four test sites. In addition, each laboratory tested samples from their own serum banks. The test detected antibodies in 32 of 36 samples (91%) from people with Brugian filariasis and in 96 of 98 samples (98%) from people with Bancroftian filariasis. Specificity testing showed that many serum or plasma samples from patients with other filarial infections such as onchocerciasis had positive antibody tests. Specificity was otherwise excellent, although 3 of 30 samples from patients with ascariasis and 4 of 51 with strongyloidiasis had positive antibody tests; it is likely that some or all of these people had previously lived in filariasis-endemic areas. Antibody test results obtained with eluates from blood dried on filter paper were similar to those obtained with plasma tested at the same dilution. This test may be helpful for diagnosing LF in patients with clinical signs of filariasis. It may also be a useful tool for use in LF endemic countries to monitor the progress of filariasis elimination programs and for post-MDA surveillance.


Transfusion | 2002

Transmission of Babesia microti in Minnesota through four blood donations from the same donor over a 6‐month period

Barbara L. Herwaldt; David F. Neitzel; Jed B. Gorlin; Kathryn A. Jensen; Elizabeth H. Perry; William R. Peglow; Susan B. Slemenda; Kimberly Y. Won; Eva K. Nace; Norman J. Pieniazek; Marianna Wilson

BACKGROUND : Babesiosis is a tick‐borne zoonosis caused by intraerythrocytic protozoa. More than 40 US cases of Babesia microti infection acquired by blood transfusion have been reported. This report describes the identification of a transfusion‐associated case of babesiosis and the subsequent identification of the infected blood donor and three other infected recipients of cellular blood components from three other donations by this donor.


PLOS Neglected Tropical Diseases | 2013

Transmission assessment surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation.

Brian K. Chu; Michael S. Deming; Nana-Kwadwo Biritwum; Windtaré Roland Bougma; Ameyo M. Dorkenoo; Maged El-Setouhy; Peter U. Fischer; Katherine Gass; Manuel Gonzalez de Peña; Leda Mercado-Hernandez; Dominique Kyelem; Patrick J. Lammie; Rebecca M. Flueckiger; Upendo Mwingira; Rahmah Noordin; Irene Offei Owusu; Eric A. Ottesen; Alexandre L. Pavluck; Nils Pilotte; Ramakrishna U. Rao; Dilhani Samarasekera; Mark A. Schmaedick; Sunil Settinayake; Paul E. Simonsen; Taniawati Supali; Fasihah Taleo; Melissa Torres; Gary J. Weil; Kimberly Y. Won

Background Lymphatic filariasis (LF) is targeted for global elimination through treatment of entire at-risk populations with repeated annual mass drug administration (MDA). Essential for program success is defining and confirming the appropriate endpoint for MDA when transmission is presumed to have reached a level low enough that it cannot be sustained even in the absence of drug intervention. Guidelines advanced by WHO call for a transmission assessment survey (TAS) to determine if MDA can be stopped within an LF evaluation unit (EU) after at least five effective rounds of annual treatment. To test the value and practicality of these guidelines, a multicenter operational research trial was undertaken in 11 countries covering various geographic and epidemiological settings. Methodology The TAS was conducted twice in each EU with TAS-1 and TAS-2 approximately 24 months apart. Lot quality assurance sampling (LQAS) formed the basis of the TAS survey design but specific EU characteristics defined the survey site (school or community), eligible population (6–7 year olds or 1st–2nd graders), survey type (systematic or cluster-sampling), target sample size, and critical cutoff (a statistically powered threshold below which transmission is expected to be no longer sustainable). The primary diagnostic tools were the immunochromatographic (ICT) test for W. bancrofti EUs and the BmR1 test (Brugia Rapid or PanLF) for Brugia spp. EUs. Principal Findings/Conclusions In 10 of 11 EUs, the number of TAS-1 positive cases was below the critical cutoff, indicating that MDA could be stopped. The same results were found in the follow-up TAS-2, therefore, confirming the previous decision outcome. Sample sizes were highly sex and age-representative and closely matched the target value after factoring in estimates of non-participation. The TAS was determined to be a practical and effective evaluation tool for stopping MDA although its validity for longer-term post-MDA surveillance requires further investigation.


PLOS Neglected Tropical Diseases | 2014

Seroprevalence and spatial epidemiology of lymphatic filariasis in American Samoa after successful mass drug administration

Colleen L. Lau; Kimberly Y. Won; Luke Becker; Ricardo J. Soares Magalhaes; Saipale Fuimaono; Wayne Melrose; Patrick J. Lammie; Patricia M. Graves

Background As part of the Global Programme to Eliminate Lymphatic Filariasis (LF), American Samoa conducted mass drug administration (MDA) from 2000–2006, and passed transmission assessment surveys in 2011–2012. We examined the seroprevalence and spatial epidemiology of LF post-MDA to inform strategies for ongoing surveillance and to reduce resurgence risk. Methods ELISA for LF antigen (Og4C3) and antibodies (Wb123, Bm14) were performed on a geo-referenced serum bank of 807 adults collected in 2010. Risk factors assessed for association with sero-positivity included age, sex, years lived in American Samoa, and occupation. Geographic clustering of serological indicators was investigated to identify spatial dependence and household-level clustering. Results Og4C3 antigen of >128 units (positive) were found in 0.75% (95% CI 0.3–1.6%) of participants, and >32 units (equivocal plus positive) in 3.2% (95% CI 0.6–4.7%). Seroprevalence of Wb123 and Bm14 antibodies were 8.1% (95% CI 6.3–10.2%) and 17.9% (95% CI 15.3–20.7%) respectively. Antigen-positive individuals were identified in all ages, and antibody prevalence higher in older ages. Prevalence was higher in males, and inversely associated with years lived in American Samoa. Spatial distribution of individuals varied significantly with positive and equivocal levels of Og4C3 antigen, but not with antibodies. Using Og4C3 cutoff points of >128 units and >32 units, average cluster sizes were 1,242 m and 1,498 m, and geographical proximity of households explained 85% and 62% of the spatial variation respectively. Conclusions High-risk populations for LF in American Samoa include adult males and recent migrants. We identified locations and estimated the size of possible residual foci of antigen-positive adults, demonstrating the value of spatial analysis in post-MDA surveillance. Strategies to monitor cluster residents and high-risk groups are needed to reduce resurgence risk. Further research is required to quantify factors contributing to LF transmission at the last stages of elimination to ensure that programme achievements are sustained.

Collaboration


Dive into the Kimberly Y. Won's collaboration.

Top Co-Authors

Avatar

Patrick J. Lammie

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Eva K. Nace

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Mark L. Eberhard

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jeffrey W. Priest

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marianna Wilson

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Peter U. Fischer

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Maurice R. Odiere

Kenya Medical Research Institute

View shared research outputs
Top Co-Authors

Avatar

Cara C. Jones

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Delynn M. Moss

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge